Incidence of cholangiocarcinoma in PSC after long-time treatment with ursodeoxycholic acid.

[Guest guest]

Eur J Gastroenterol Hepatol. 2007 Jun;19(6):487-91.

The incidence of cholangiocarcinoma

in primary sclerosing cholangitis

after long-time treatment with ursodeoxycholic acid.

Rudolph G, Kloeters-Plachky P, Rost D, Stiehl A.

Department of Medicine, University of Heidelberg,

FRG.

BACKGROUND/AIMS: Cholangiocarcinoma represents a serious complication of

primary sclerosing cholangitis. Ursodeoxycholic acid may

possibly influence the incidence of cholangiocarcinoma in man.

The aim of this study was to evaluate the incidence rate of

cholangiocarcinoma in a large group of primary sclerosing

cholangitis patients after long-time treatment with ursodeoxycholic acid.

PATIENTS AND METHODS: From May 1987 up to May 2005 a

total of 150 patients with primary sclerosing cholangitis but without evidence of cholangiocarcinoma at

entry were included in the study. All patients were

treated with ursodeoxycholic acid and controls were

performed in at least yearly intervals. RESULTS: The

median treatment time of the 150 patients was 6.4 years. Altogether

five patients developed a cholangiocarcinoma during treatment yielding a rate

of 3.3%. The patients developed 0.58

cholangiocarcinoma per 100 patient-years in years 0-2.5, 0.59

cholangiocarcinoma in years 2.5-8.5, and no cholangiocarcinoma thereafter up to

18 years after entry into the study. The Kaplan-Meier

estimate of cholangiocarcinoma incidence during ursodeoxycholic

acid treatment reached a plateau after 8.3 years

SUMMARY AND CONCLUSION: The annual incidence rate of

cholangiocarcinoma in primary sclerosing cholangitis treated with ursodeoxycholic

acid is lower than expected and decreases with time of treatment.

PMID: 17489059 [PubMed - in process]

Barb in Texas - Together in the Fight, Whatever it Takes!

Son Ken (33) UC 91 - PSC 99 Listed 7/21 @ Baylor Dallas